Ventricular Tachycardia and Fibrillation: Amiodarone as a Safety and Prophylactic

Abstract

Background: The best antiarrhythmic drug on the market right now for treating both atrial and ventricular arrhythmias is amiodarone. This is a derivative of iodinated benzofuran that has shown promise in treating a variety of cardiac arrhythmias, such as life-threatening ventricular arrhythmias, paroxysmal supraventricular tachycardias, and atrial fibrillation. Objective: To assess the status of amiodarone with therapeutic doses in the Bangladeshi population. Materials and Method: The quasi experimental study was conducted in the Department of Cardiology, Northeast Medical College, Sylhet during April, 2022 to March, 2023 patients got admitted in the Department of Cardiology, NMCH, Sylhet, consecutive patients who had been treated with amiodarone for arrhythmia were included in this study. Patients without an amiodarone prescription were assumed and patients who will not give informed written consent were excluded in this study. Result: In multivariable logistic regression, bradycardia or conduction disturbance, amiodarone daily dose (≥300 mg), and duration of amiodarone (>4 month) were substantially (p<0.05) linked with deleterious effects of amiodarone. Conclusion: The most common adverse event was bradycardia or conduction disturbance followed by thyroid toxicity, hepatic toxicity, eye toxicity and pulmonary toxicity. Bradycardia or conduction disturbance, amiodarone daily dose (≥300 mg) and duration of amiodarone (>4 month) was found to be significantly associated with adverse effects of amiodarone.